RxDoctor Payments Data

Kathryn Cunningham, MD

Urology · Oklahoma City, OKNPI 1992055990

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,250 of the $10,807 with a category attached, or 67.1%. 43 manufacturers reported payments, led by Medtronic at 24.4% of the total.

$10,807in general payments, 2019–2025

Across 263 payments — averaging $41.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Teleflex LLC$2K
  • Coloplast$1K
  • Astellas Pharma US Inc$1K
  • Boston Scientific$907
  • Procept Biorobotics Corporation$618
  • plus $2K from 37 others

What the payments were for

  • Travel & lodging$2,82326%
  • Food & beverage$7,25067%
  • Education$7337%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,807 in reported general payments places this provider in the 80th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$438,504
Medicare patients
773
Services billed
38,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron483$291,297
GemtesaVibegron107$73,026
PremarinEstrogens, Conjugated70$31,142
Methenamine Hippurate107$8,663
Mirabegron ErMirabegron15$7,883
Tamsulosin Hcl312$4,843
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst145$4,155
Estradiol72$4,085
Gentamicin Sulfate50$3,408
Finasteride223$3,382
Trospium Chloride43$3,012
Fesoterodine Fumarate ErFesoterodine Fumarate30$2,671
Solifenacin Succinate52$2,035
Testosterone Cypionate51$2,003
Potassium Citrate ErPotassium Citrate19$1,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,005$291,297483 claims
Sumitomo Pharma America, Inc.Gemtesa$51$73,026107 claims
PfizerPremarin$116$31,14270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →